Assembly Biosciences (ASMB)
PRICE RANGE CHANGE
Trading: NO POSITION @ $21.25
Signal Strength: WEAK
Indicator MUST BE USED in additional to another technical indicator to confirmation for trading entry. Indicator can be applied to the short term timeframe but is only able to give and indication of the strength of the buyers versus sellers at the market close. This bar analysis can provide guidance on the daily battle between sellers and buyers from the companies recent trading.
Assembly Biosciences (NASDAQ:ASMB)Neither buyer or seller are in control at the close of the market for Assembly Biosciences. This is the first day of closing price in the middle range for ASMB showing a lack of direction in the first timeframe & highlights the lack of commitment from both the buyers & sellers. Over the last 12 months there has been 2 trading days with the closing price in the middle part of the range giving a confirmation ratio of 0.8%. Over the last month there has been 2 trading days with the closing price in the middle range giving a confirmation ratio of 16.7%. Currently this quarter, closing price has spent 2 days in the middle price range giving a ratio of 0.2x.
Where the closing price fall within the day’s trading range highlights whether are in control.
[Calculations] Close Today Versus Range Today (CTRT):
1) When the closing price is near the high of the day buyers were in control at the close of the trading session;
2) When the closing price is near the low of the day sellers were in control at the close of the trading session;
3) When the closing price is near the middle of the day’s range where neither the buyers or sellers were in control at the close of the trading session;
PROFILE: Assembly Biosciences (ASMB)
Stock Exchange: NASDAQ
Company: Assembly Biosciences
Ticker Codes: | ASMB | NASDAQ:ASMB |
Assembly Biosciences, Inc. operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States. It is involved in the development of core protein allosteric modulators that modulate the HBV core protein at various points in the viral lifecycle. The company also develops microbiome program, a platform that includes the identification and selection process to strain isolation and growth under current good manufacturing practice conditions; and a patent pending delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. In addition, it engages in the development of product candidates for various disease indications, such as ulcerative colitis, Crohn's disease, irritable bowel syndrome, non-alcoholic steatohepatitis, immuno-oncology, and clostridium difficile infections by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of selected microbiome gastrointestinal programs. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana.
Close vs RangeDownload
|GOGO Gogo Inc||4.09||8.5||2,239,407||1||BULLISH|
|INSY Insys Theraptcs||4.66||8.1||662,007||1||BULLISH|
|NYNY Empire Resorts Inc||14.31||6.4||29,432||1||BULLISH|
|FPRX Five Prime||10.64||6||473,429||1||BULLISH|
|NCBS Nicolet Bankshares||54.98||5.7||16,731||1||BULLISH|
|KEYW Keyw Holding Corp||6.66||5.4||386,172||1||BULLISH|
|GT Goodyear Tire Rubber||20.27||3.8||7,346,405||1||BULLISH|
|OFLX Omega Flex Inc||61||3.5||4,163||1||BULLISH|